Status:
COMPLETED
Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer
Lead Sponsor:
Nantes University Hospital
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Nivolumab is a selective monoclonal antibody that binds to the Programmed cell Death 1 (PD-1) receptor and causes reduced tumor growth. It is currently approved in France in many indications. The firs...
Eligibility Criteria
Inclusion
- Patients with metastatic melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma treated with nivolumab monotherapy
- Patients whose nivolumab treatment was initiated between 2015 and 2020
- Patients with health insurance
Exclusion
- Patients whose nivolumab treatment initiated in 2017 in mg/kg has progressed to a fixed dose in the 1st year of treatment
- Patients treated with nivolumab in the adjuvant setting for melanoma with lymph node involvement or metastatic disease and who have undergone complete resection (Approval in 2018 for this indication)
- Patients whose nivolumab treatment has been initiated in 2018
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
40000 Patients enrolled
Trial Details
Trial ID
NCT05380336
Start Date
January 1 2014
End Date
December 31 2021
Last Update
June 1 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.